Weekly low-dose docetaxel in the treatment of lung metastases from angiosarcoma of the head

Yamada, Masahito; Hatta, Naohito; Mizuno, Mihoko; Oishi, Naoki; Takehara, Kazuhiko

doi:10.1111/j.1365-2133.2005.06503.x

Cited by 16 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sorafenib is an oral multikinase inhibitor that acts by inhibiting tumor growth with antiproliferative and antiangiogenic characteristics. Paclitaxel combined with sorafenib maybe more useful [3,[25][26][27]. The systemic administration of high doses of rIL-2 has been highly effective and induced the regression of pulmonary metastasis [4].…”

Section: Discussionmentioning

confidence: 99%

Angiosarcoma of the lung: 2 cases report and literature reviewed

Chen¹,

Guo²,

Yang³

et al. 2010

Lung Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Angiosarcoma of the lung: 2 cases report and literature reviewed

Chen¹,

Guo²,

Yang³

et al. 2010

Lung Cancer

View full text Add to dashboard Cite

“…Based on the finding that the origin of both Kaposi sarcoma and AS is the endothelial cell, it is conceivable that the antiangiogenic activity of paclitaxel and docetaxel is a mechanism that contributes to its efficacy in angiosarcoma 5. Recently, there have been a few reports showing the efficacy of docetaxel for AS 8–10. In the current report, we describe our experience of favorable clinical response in 6 of 9 patients who were treated with docetaxel.…”

Section: Discussionmentioning

confidence: 87%

“…Paclitaxel has unique activity not only in breast cancer but also in AS5, 6 and Kaposi sarcoma,7 and it has been demonstrated that paclitaxel is effective in the treatment of AS. However, few patients who received treatment with docetaxel have been reported 8–10. Therefore, we reviewed our experience of chemotherapy in adult patients with cutaneous AS using docetaxel.…”

mentioning

confidence: 99%

Docetaxel: A therapeutic option in the treatment of cutaneous angiosarcoma

Nagano

Yamada

Ikeda

et al. 2007

Cancer

127

View full text Add to dashboard Cite

BACKGROUND.Effective treatment options are limited for patients with cutaneous angiosarcoma (AS). Docetaxel, a member of the taxane family of drugs, reportedly has been effective in the treatment of lung, head and neck, and breast cancers. Another taxane drug, paclitaxel, reportedly had unique activity in the treatment of AS of the scalp and neck and acquired immunodeficiency syndrome‐related Kaposi sarcoma. Therefore, the authors hypothesized that docetaxel may be of value in the treatment of cutaneous AS that is resistant to conventional therapy. However, there were only 3 case reports of the successful treatment of AS in elderly patients using docetaxel in combination with surgery and radiotherapy.METHODS.This was a retrospective trial. After written informed consent was obtained, docetaxel was administered intravenously at a dose of 25 mg/m2 for 1 hour weekly over a period of 8 weeks on the basis of previous reports. This treatment regimen was received by 9 patients with cutaneous AS who were treated at Kobe University Hospital between January 2003 and October 2006.RESULTS.Six of the 9 patients who received treatment achieved major responses, including 2 complete responses and 4 partial responses. Neutropenia and peripheral neuropathy were not prominent, although severe radiation dermatitis enhanced by the docetaxel was observed in 3 patients. There were no deaths attributable to this therapy.CONCLUSIONS.The current study demonstrated that docetaxel was effective in patients with cutaneous AS. Cancer 2007. © 2007 American Cancer Society.

show abstract

“…In most of the cases, treatment is administered on a weekly basis and affects scalp or skin AS. In that setting, most of the reports describe complete or partial responses with short progressionfree survival up to 3-4 months [17][18][19][20][21][22][23]. Angiosarcoma of liver [11] Particularly frequent in industrial workers exposed to vinyl chloride (used in the production of synthetic rubber) Frequent in workers exposed to insecticides, such as arsenics Primaries arose from viscera in 8 cases; from breast in 10 cases; and from soft tissue, skin or, scalp in 12 cases.…”

Section: Treatment Of Metastatic Angiosarcomasmentioning

confidence: 99%

“…Numerous case reports suggest some kind of clinical benefit with paclitaxel [17][18][19] or docetaxel [20][21][22][23] in patients with unresectable or metastatic AS. In most of the cases, treatment is administered on a weekly basis and affects scalp or skin AS.…”

Section: Treatment Of Metastatic Angiosarcomasmentioning

confidence: 99%

Angiosarcomas and Taxanes

Penel

Lansiaux

Adenis

2007

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Angiosarcomas (AS) are a heterogeneous group of rare and aggressive malignancies. The best treatment of localized AS includes wide resection following by adjuvant radiation therapy as possible. The current standard treatment of metastatic AS remains a doxorubicin-based regimen. This treatment provides a median progression-free survival and a median overall survival of about 4 and 8 months, respectively. Numerous case reports and retrospective studies have suggested that taxanes (paclitaxel or docetaxel) may provide some objective responses. The French Sarcoma Group has conducted a phase II clinical trial, which states the benefit of weekly paclitaxel in patients with unresectable or metastatic AS. After 2 cycles, the non-progression rate was 78% and complete histological responses were observed in 3 out of 30 cases. Further clinical studies are needed to confirm clinic impact of weekly paclitaxel on survival and to assess the role of taxanes in the multidisciplinary treatment of AS.

show abstract

Weekly low-dose docetaxel in the treatment of lung metastases from angiosarcoma of the head

Cited by 16 publications

References 10 publications

Angiosarcoma of the lung: 2 cases report and literature reviewed

Angiosarcoma of the lung: 2 cases report and literature reviewed

Docetaxel: A therapeutic option in the treatment of cutaneous angiosarcoma

Angiosarcomas and Taxanes

Contact Info

Product

Resources

About